A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. [electronic resource]
Producer: 20140414Description: 1182-91 p. digitalISSN:- 1573-0646
- Adult
- Aged
- Aged, 80 and over
- Amyloid Precursor Protein Secretases -- antagonists & inhibitors
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Benzazepines -- administration & dosage
- Calcium-Binding Proteins -- metabolism
- Fatigue -- chemically induced
- Female
- Humans
- Intercellular Signaling Peptides and Proteins -- metabolism
- Male
- Membrane Proteins -- metabolism
- Middle Aged
- Mucositis -- chemically induced
- Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- administration & dosage
- Receptor, Notch3
- Receptors, Notch -- metabolism
- Serrate-Jagged Proteins
- Sirolimus -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.